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Abstract
Background: The medico-economic impact of smoking cessation considering a smoking patient with chronic obstructive
pulmonary disease (COPD) is poorly documented.
Objective: Here, considering a COPD smoking patient, the specific burden of continuous smoking was estimated, as well as
the effectiveness and the cost-effectiveness of smoking cessation.
Methods: A multi-state Markov model adopting society’s perspective was developed. Simulated cohorts of English COPD
patients who are active smokers (all severity stages combined or patients with the same initial severity stage) were
compared to identical cohorts of patients who quit smoking at cohort initialization. Life expectancy, quality adjusted life-
years (QALY), disease-related costs, and incremental cost-effectiveness ratio (ICER: £/QALY) were estimated, considering
smoking cessation programs with various possible scenarios of success rates and costs. Sensitivity analyses included the
variation of model key parameters.
Principal Findings: At the horizon of a smoking COPD patient’s remaining lifetime, smoking cessation at cohort
intitialization, relapses being allowed as observed in practice, would result in gains (mean) of 1.27 life-years and 0.68 QALY,
and induce savings of 21824 £/patient in the disease-related costs. The corresponding ICER was 22686 £/QALY. Smoking
cessation resulted in 0.72, 0.69, 0.64 and 0.42 QALY respectively gained per mild, moderate, severe, and very severe COPD
patient, but was nevertheless cost-effective for mild to severe COPD patients in most scenarios, even when hypothesizing
expensive smoking cessation intervention programmes associated with low success rates. Considering a ten-year time
horizon, the burden of continuous smoking in English COPD patients was estimated to cost a total of 1657 M£ while 452516
QALY would be simultaneously lost.
Conclusions: The study results are a useful support for the setting of smoking cessation programmes specifically targeted to
COPD patients.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of disability and mortality worldwide. COPD morbidity and
mortality are expected to rise substantially in coming decades, and
COPD is predicted to become the fourth leading cause of death by
2030 [1]. In industrialised countries, smoking is the main risk
factor for COPD [2]. Once COPD is established, smoking is also
associated with more rapid disease progression: pulmonary
function declines twice as fast in continuing COPD smokers than
in sustained COPD quitters [3]. Society’s view of smoking has
changed profoundly in recent decades [4], leading to prevention
campaigns and legal measures aiming at reducing tobacco
consumption [5], and there are now both societal and personal
reasons why COPD smokers should quit. However, many such
patients consider they are too old to benefit from smoking
cessation, or that the damage to their health is already inexorable
[6]. Shahab et al estimated that COPD smokers represent 4.6% of
the English population over 35 years of age [7].
The cost-effectiveness of smoking cessation programmes has
been thoroughly studied (see for example [8]), but few studies have
focused on the medico-economic impact of changes in the smoking
status of COPD patients. Only two studies have estimated the cost-
effectiveness of smoking cessation programmes for COPD patients
at the population scale [9,10]. Based on a model including the
future estimated cases of COPD over the next 25 years in the
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24870Netherlands, these studies indicated that smoking cessation
programmes would be cost-effective. In particular, a smoking
cessation programme combining intensive counseling and phar-
macotherapy with a 12.3% 12-month abstinence rate and applied
to 50% of the cohort of Dutch COPD smokers would result in an
incremental cost-effectiveness ratio (ICER) of 2400 J per quality
adjusted life-year (QALY) gained, as compared to usual care [9].
Here, a patient-centered model adapted to English COPD
smokers was developed for estimating the impact of smoking
cessation according to disease severity. A cohort of such patients
was simulated, and the patients were followed-up until death. In a
first step, the aim was to estimate what a COPD smoker who stops
smoking should expect in terms of health gains: surprisingly, the
impact of smoking cessation on such a patient’s life expectancy and
QALYs has never been reported. In a second step, we included
costs of the disease and performed a cost-effectiveness study
exploring several scenarios with the impact of smoking cessation
programmes having different costs and efficacies, and applied to
patients at different moments of disease progression.
Methods
The study adopted society’s viewpoint and the time horizon
extended from initial smoking cessation by an English COPD
patient to his or her death (all-cause mortality in COPD patients).
All costs are expressed in 2010 pounds Sterling (£) and health
outcomes are expressed as life-years (LY) and QALY. As
recommended by the National Institute for Health and Clinical
Excellence (NICE) [11], all costs and QALY values were
discounted at a rate of 3.5%. The cost-effectiveness criterion for
a given scenario was the incremental cost-effectiveness ratio
(ICER), i.e. the ratio of the difference in costs between the
intervention and non intervention to the corresponding difference
in QALY, as recommended by international guidelines [12].
Intervention
In a first step, this study estimated the burden of continuous
smoking: An hypothetical cohort of standard English COPD
continuous smokers cohort was simulated and compared to a
similar hypothetical cohort of patients who all stop smoking at
cohort initialization and remain sustained quitters. To analyse the
potential difference in the continuous smoking according to
COPD severity, we also simulated cohorts in which all the patients
had the same initial severity.
In a second step, the study explored in detail the impact of
smoking cessation, whether following a specific intervention
programme where various success rate and intervention cost were
considered (see also further details below in Sensitivity Analysis) or
not: the above-mentioned continuous smokers’ cohort (further
referred to as ‘‘no intervention’’) was compared to a similar
hypothetical cohort where a proportion of patients stop smoking at
cohort initialization (further referred to as ‘‘intervention’’), but a
yearly turnover of smoking status was allowed in both cohorts. The
comparison of these two cohorts is further referred to as the
‘‘reference case’’, and allows estimating the impact of smoking
cessation in a typical COPD smoker. To analyse the potential
difference in the impact of smoking cessation according to COPD
severity, we also simulated cohorts in which all the patients had the
same initial severity.
Monte-Carlo Simulation of a cohort of English COPD
smokers
Multi-state Markov modeling is a useful tool for representing a
given disease [13]. Evolution of the disease in a cohort of patients
is reflected by the changes in the relative proportions of patients in
the different states along time. The time horizon of the analysis is
divided into equal increments of time (e.g. year) and at each cycle,
the process of transitions from one state to another (e.g. mild to
moderate, or mild to death) is repeated, resulting in a given
proportion of patients in each state at a given time. Such
transitions as well as events that might influence the transitions
(e.g. death not only depends on the grading of the disease but also
on age, transitions rates may depend on smoking status, …)
depend on probabilities that might vary with time (e.g. age-specific
mortality). There are two ways of studying a Markov model, the
cohort simulation and the Monte Carlo simulation. In the cohort
simulation, all individuals are considered as a whole, and one only
directly calculates the expected proportions of patients in the
different states along time. In the Monte Carlo simulation
approach, each patient of the cohort is individually simulated,
each event being randomly chosen thanks to a pseudo-random
number generator. Therefore, Monte Carlo simulations have the
advantage of providing not only expected values, but allowing the
examination of the associated variability.
We developed a multi-state Markov model based on the natural
history of COPD (Figure 1). Using Monte Carlo simulation, each
patient in the cohort was simulated until death (maximum age was
set at 110 years). Each iteration was a one-year period during
which the patient might either die (death was the final and
absorbing state) or being subjected to a transition rate from his
current severity stage to the next. Parameter values used in the
model are summarized in Table 1 and are detailed below.
In a simulated cohort, a patient enters with a given COPD
severity state, age, and smoking status. The severity states were
those of the Global Initiative for Chronic Obstructive Lung
Disease [14], namely GOLD1, GOLD 2, GOLD 3, GOLD 4.
Shahab et al have reported the distribution of the English
COPD patients in stage GOLD1, GOLD2, and GOLD3+-
GOLD4 according to smoking status [7]. As reported for
Sweden [15], we postulated that respectively 5/6 and 1/6
patients were at stages GOLD3 and GOLD4. Shahab reported
prevalence data for 10-year age classes; we considered that the
age distributions in stages GOLD3 and GOLD4 were identical,
and that the prevalence of COPD was uniform within each 10-
year age class.
The initial distributions of age according to severity stages were
set by adjusting Shahab’s prevalence data to age distribution in
England, as issued from the Office For National Statistics [16].
Thus, an initial cohort of individuals aged from 40 to 89 years was
created (see supporting information, Table S1), likely to reflect the
current distribution of English COPD smokers.
All simulations were performed with TreeAge Pro software
( 2007, TreeAge Software, Inc. Williamstown, MA, USA). Each
simulated cohort was composed of 10
6 patients.
Disease progression parameter values: transitions from
one severity stage to the next and exacerbation rates
The transition rates from a given severity stage to the next
during a one-year iteration depended on the current severity stage,
patient age, and smoking status. As detailed in the supporting
information (Table S2), the corresponding transition probability
table was built by combining transition probabilities from the
Framingham cohort, as reported by Nielsen et al. [17], with
transition probabilities according to smoking status, as reported by
Hoogendoorn et al. [10]. The probability of experiencing one or
more exacerbations was chosen according to Soler-Cataluna et al.
[18] and depended on the severity stage.
Smoking Cessation in COPD Smokers
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24870Figure 1. Flowchart describing the Markov multi-state model used. X value is 1, 2, 3, or 4, respectively corresponding to GOLD 1, GOLD 2,
GOLD 3 and GOLD 4 stages. Each of these healthcare states is associated with a corresponding utility and cost.
*Value ‘‘X+1’’ does not exist for X=4
(stage GOLD4). Nodes marked with an ‘‘M’’ represent Markov process chance nodes, while full square, full circle, and full triangle nodes correspond to
decision, chance, and terminal nodes, respectively. Evolution of the cohort is made with one-year iteration step. Each patient is followed until death
(all causes of death in COPD patients). At each iteration (Markov node), a given patient in a given X severity stage, is first subjected to a potential
change in his/her smoking status, reflecting the background turnover observed in COPD patients (top). As indicated in Table 1, turnover probabilities
were constant over age and COPD severity stages. Then (bottom), he might experience exacerbations (that only depend on patient’s COPD current
severity stage, as indicated in Table 1). In the end, the patient may 1) stay in the same severity stage, 2) pass to the next severity stage (X+1), 3) die.
Transition probabilities from one stage to the next depend on age, severity stage, and smoking status (see parameter values in Table S2 in supporting
information). Transition probabilities to death depend on the same parameters and in addition, on exacerbation status (see parameter values in in
Table S3 in supporting information). As compared to current smokers, ex-smokers had a lower disease progression, and a lower probability of death.
doi:10.1371/journal.pone.0024870.g001
Table 1. Parameter values used in the Monte-Carlo simulations (reference case).
Parameter COPD severity stage
GOLD1 GOLD2 GOLD3 GOLD4
COPD severity distribution (% of patients) 35.08 48.17 13.96 2.79
Annual smoking transition rates (% of patients)
Quit smoking 4.7 whatever the severity stage
Resume smoking 2.6 whatever the severity stage
Exacerbation rates (% of patients) [0 exacerbation ; $1 exacerbation] [75.00; 25.00] [60.55; 39.45] [55.90; 44.10] [34.30; 65.70]
Age distribution per severity stage Based on references 7 and 15; see supporting information, Table S1
Annual transition rate to next severity stage Based on references 10 and 17; see supporting information, Table S2
Annual mortality rate per severity stage Based on references 20 and 21; see supporting information, Table S3
Health utility (QALY) [0 exacerbation ; $1 exacerbation] [0.897; 0.895] [0.755; 0.736] [0.748; 0.726] [0.549; 0.535]
Annual cost of COPD (£/patient)* 220 726 3758 9470
COPD, chronic obstructive pulmonary disease; QALY, quality adjusted life-years.
*The COPD annual cost included direct (drugs. hospitalization. outpatient care. equipment aids. oxygen therapy) and indirect cost (disability pensions. absence from
work).
doi:10.1371/journal.pone.0024870.t001
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The specific mortality table used in the present study simulations
is detailed in Table S3 of the supporting information. The table was
built using three information sources: all-cause mortality data (codes
A00-Y89) for the UK general population in 2007 [19], data from
Mannino et al [20] for taking into account excess mortality
associated with COPD, and data from Ekberg-Aronsson et al. [21]
for taking into account the smoking status of COPD patients.
Disease progression parameter values: smoking status
A first particular scenario compared a simulated cohort where all
COPD patients remain continuous smokers during their remaining
lifetime to an identical simulated cohort of COPD patients who quit
smokingat simulation initiationand remainex-smokers duringtheir
remaining lifetime. However, although such a particular scenario
allows estimating the raw impact of continuous smoking in COPD
patients, all other simulations were conducted assuming quit and
relapse events to occur during a patient remaining lifetime, as
observed in practice:during a one-year iteration, the probabilities of
smoking cessation by smokers and of relapse by ex-smokers were
respectively setto0.047 and 0.026,accordingto Hoogendoornet al.
[10]. These probabilities were constant over time, whatever the
patient’s age and severity stage. Importantly, these quit and relapse
transitions, kept in every cohort simulation, resulted in background
yearly smoking status changes, both with and without interventions.
As compared to current smokers, ex-smokers had a lower disease
progression (see supporting information. Table S2), and a lower
probability of death (see supporting information Table S3, n.b. a
lower probability of exacerbations for ex-smokers was also explored
in the sensitivity analysis).
Disease progression parameter values: cost and health
utilities
Costs were based on data from Jansson et al. [22] and included
direct and indirect costs. As the study by Jansson et al. was based
on the British Thoracic Society classification of COPD severity,
these costs were adapted to the GOLD classification. Moreover, as
the initial estimates by Jansson et al. were given in 2002 Swedish
Crowns, costs were discounted (3.5% rate), converted into 2010
pounds Sterling, and corrected with the Big Mac index [23].
Health utilities were expressed in QALY and based on the
estimates reported by Borg et al and Cataluna et al. [18,24] for
COPD patients: respectively 0.8971, 0.7511, 0.7481 and 0.5493
QALY for stable (i.e. exacerbation-free during a one-year iteration)
GOLD1, GOLD2, GOLD3 and GOLD4 patients; respectively
0.8951, 0.7364, 0.7261 and 0.5357 QALY, for unstable patients.
Sensitivity analysis
Various scenarios were examined in order to explore the impact
of varying the model parameter values on the simulation outputs
(costs, QALY and ICER). In particular, we explored the
hypothesis of smoking cessation being due to a smoking cessation
programme, allowing the cost and quit rate of such a programme
to vary. The remaining parameters that were also allowed to vary
were the transition rate from one severity stage to the next,
mortality and exacerbation rates, management costs, discounting
rates and smoking cessation rates.
Results
When considering cohorts combining all severity stages at
cohort initiation, the simulations estimated that COPD patients
remaining continuous smokers until their end of life had a mean
remaining lifespan of 15.60 (mean) LY corresponding to 8.47
QALY. Compared to these patients, sustained quitters were
estimated to gain 2.73 LY and 1.225 QALY (Table 2).
Considering patient’s lifespan, the additional disease-related cost
of continuous smoking versus sustained abstinence was 1661 £ per
patient. Health gains associated with sustained abstinence
decreased with disease severity status at cohort initiation, from
3.17 to 1.92 LY and from 1.43 to 0.657 QALY for GOLD1 and
GOLD4 patients, respectively (Table 2). The simulations estimat-
ed that during a 10-year period, the specific burden of continuous
smoking (as compared to sustained abstinence) in the current
1400000 English COPD smokers resulted in total disease-related
costs of 1657 M£ together with losses of 452516 QALY.
All further results concern simulations where relapse and quit
events were allowed (see methods and Table 1). When considering
cohorts combining all stages, smoking cessation by a patient at
cohort entry resulted in health gains of 1.27 LY and 0.68 QALY
(Table 3) at the horizon of his remaining lifetime. In addition, cost
savings amounted to 1824 £ per patient over his/her remaining
lifetime, with a corresponding ICER of 22686 £/QALY. The
simulation outputs (life expectancy, QALY and cost) varied
according to a given patient’s initial COPD stage (Table 3).
Overall, the health gains associated with smoking cessation at
cohort entry decreased as baseline COPD severity increased (from
0.72 QALY for patients initially in stage GOLD1, to 0.69, 0.64,
and 0.42 QALY for patients initially in stages GOLD2, GOLD3
and GOLD4, respectively). We observed savings for patients
initially in stage GOLD1 or GOLD2, with the most favourable
ICER observed for GOLD2 patients: 24624 £/QALY. GOLD3
and GOLD4 were associated with costs with the less favourable
ICER of 17546 £/QALY observed for patients initially in stage
GOLD4, a value near the NICE threshold (20000 £/QALY) for
declaring an intervention worthwhile (i.e. cost-effective).
Sensitivity analyses were then used to explore how the results
were affected when the parameter values were varied (Table 4 and
Figure 2). Considering a cohort of COPD smokers combining all
stages at cohort initiation, all simulations corresponding to the
reference case scenario showed that a smoking cessation
intervention would lead to cost savings, whatever its cost
(Table 4). When the percentage of quitters after the smoking
cessation intervention was varied, only 3 scenarios resulted in
ICERs.5000 £/QALY. The least favourable situation, 14965 £/
QALY, a figure still below the NICE threshold, corresponded to
an intervention having a cost of 1000£ and an initial rate of 1/12
quitters after the smoking cessation intervention. When the results
were analysed according to initial severity, smoking cessation
appeared especially favourable for GOLD2 patients. Nevertheless,
even for GOLD3 patients, only one hypothesis corresponding to
an intervention having a cost of 1000£ and an initial rate of 1/12
quitters after the smoking cessation intervention exceeded the
threshold of a ‘‘worthwhile’’ ICERs. In contrast, ICERs derived
from simulations of patients initially at stage GOLD4 often
exceeded 20000 £/QALY, and the most favourable scenarios
were near this limit.
The results were sensitive to the transition rates from one
severity stage to the next (Figure 2, scenario K), and to an increase
in the mortality rates (Figure 2, scenarios B, C and D). The model
was not very sensitive to an exacerbation-free rate 15% higher
than that of the reference case (Figure 2, scenario H). In contrast,
when we postulated that ex-smokers experienced fewer exacerba-
tions than smokers (the two explored scenarios hypothesized that
on average, the probability of an exacerbation-free year was
respectively 15% or 30% higher in ex-smokers than in current
Smoking Cessation in COPD Smokers
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gains were observed, with the ICER rising by 42% in the most
favourable scenario. The model was not very sensitive to variations
in disease management costs: hypothesizing a 15% additional cost
for each severity stage (Figure 2, scenario G) or no cost at all for
GOLD1 patients (Figure 2, scenario J) resulted in modest changes
in the ICER estimates. When health utilities and costs were not
discounted (Figure 2, scenario F) and or when a discounting rate of
5% (Figure 2, scenario I) was applied as recommended in
international guidelines [12], the changes in the corresponding
ICERs were also modest. Overall, it’s worth to mention that all the
scenarios shown in Figure 2 remained yielding savings in terms of
the ICERs, as the percentage change relative to the reference case
(22686 £/QALY) was always below 100%.
Discussion
The proposed model allowed to estimate what represents the
specific burden of continuous smoking for a COPD smoker (as
compared to a COPD smoker becoming a sustained quitter): 2.73
LY with corresponding 1.22 QALY lost, and additional 1661 £
disease-related costs (Table 2). One might consider these patient’s
level differences between sustained smoking versus sustained
abstinence as modest. However, LY estimate is close to that of
Table 2. The burden of continuous smoking in COPD smoking patients.
Stage of the
cohort
members at
cohort
initiation Mean estimate
*
Cost
{ (£) per patient Life-years per patient QALY per patient ICER (£/QALY)
Continuous
smokers
Sustained
quitters
{
Continuous
smokers
Sustained
quitters
{
Continuous
smokers
Sustained
quitters
{
All stages
combined
27834 21661 15.60 2.73 8.471 1.225 21356
GOLD1 12196 22967 19.96 3.17 11.426 1.434 22070
GOLD2 30810 23070 14.31 2.67 7.495 1.183 22594
GOLD3 47021 3588 10.34 2.02 5.348 0.969 3703
GOLD4 72654 11530 9.83 1.92 4.142 0.657 17546
COPD, chronic obstructive pulmonary disease; QALY, quality adjusted life-years; ICER, incremental cost-effectiveness ratio: additional cost (positive values) or savings
(negative values) per unit of QALY gained.
The average age in the initial cohorts ‘‘All Stages combined’’, GOLD 1, GOLD 2, GOLD 3 and GOLD 4, was 60, 57, 60.5, 64.6 and 64.6, respectively.
*Cumulative value at the horizon of a patient’s remaining lifetime.
{Direct costs accounted for 40% of the total costs shown in the Table.
{Sustained quitter values are reported as incremental values compared to continuous smoker. A positive number denotes an increase of sustained quitter value above
continuous smoker value and a negative number a decrease of value.
doi:10.1371/journal.pone.0024870.t002
Table 3. Cost-effectiveness of smoking cessation (intervention) for a COPD smoking patient.
Stage of the
cohort
members at
cohort
initiation Mean estimate
*
Cost
{ (£) per patient Life-years per patient QALY per patient ICER (£/QALY)
No intervention Intervention
{ No intervention Intervention
{ No intervention Intervention
{
All stages
combined
28013 21824 16.51 1.27 8.810 0.679 22686
GOLD1 11612 22004 21.12 1.29 11.869 0.721 22779
GOLD2 31031 23171 15.14 1.33 7.804 0.686 24624
GOLD3 48422 1366 10.87 1.16 5.548 0.641 2133
GOLD4 75222 7349 10.33 1.11 4.288 0.419 17546
COPD, chronic obstructive pulmonary disease; QALY, quality adjusted life-years; ICER, incremental cost-effectiveness ratio: additional cost (positive values) or savings
(negative values) per unit of QALY gained.
The average age in the initial cohorts ‘‘All Stages combined’’, GOLD 1, GOLD 2, GOLD 3 and GOLD 4, was 60, 57, 60.5, 64.6 and 64.6, respectively.
*Cumulative value at the horizon of a patient’s remaining lifetime.
{Direct costs accounted for 40% of the total costs shown in the Table.
{Intervention (i.e. smoking cessation at cohort initiation) values are reported as incremental values compared to no intervention. A positive number denotes an increase
of intervention value above no intervention value and a negative number a decrease of intervention value from no intervention value.
doi:10.1371/journal.pone.0024870.t003
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doctors aged 60 years (the mean age in our COPD simulated
cohorts was 60 years) and found that sustained smoking cessation
added 3 years of life expectancy [25]. Moreover, the 1400000
English COPD smokers [16] represent 4.6% of the general
population of the same generation [7], and the gains for society at
a national level are substantial (see results).
When relapse and quit events were allowed as observed in
everydaylife,thesimulationresultsindicatedthatarandomlyselected
COPD patient who quits smoking might expect a gain of 1.27-year in
his/her remaining lifespan with corresponding 0.68 QALY. Allin all,
these resultsindicate that sustained abstinence after smoking cessation
roughly doubles the health gains when compared to smoking
cessation with relapses. Smoking cessation by English COPD patients
would also reduce COPD management costs.
The study also examines in detail the cost-effectiveness of
smoking cessation according to disease severity and the results
have practical consequences. First, whatever the disease stage
considered, smoking cessation led to modest healthcare gains
considering the remaining life of a COPD patient (Table 3). Such
a knowledge may be considered as a useful contribution for
supporting upstream public health policies in the domain of
smoking cessation programmes devoted to younger populations, in
order to decrease the number of COPD future cases. Second, the
study also suggests the development of smoking cessation
programmes targeted to specific populations of COPD patients:
smoking cessation would result in worthwhile ICERs for patients
with both mild and severe COPD in most cases, even when
hypothesizing expensive programmes and low rates of quitters
(Table 4). For example, a smoking cessation programme targeting
Table 4. Cost-effectiveness of smoking cessation according to the abstinence rate.
Stage of the cohort members at
cohort initiation (initial
abstinence rate)
COPD cost for
the remaining
lifetime (£)
Remaining life-
years
Remaining quality
adjusted life-years
(QALY)
ICER (£/QALY) according to the cost (£) of a smoking
cessation programme
0 £ 100 £ 200 £ 500 £ 1000 £
All_Stages
No intervention (0%) 28013 16.51 8.810
Reference case (100%) 21824 1.27 0.679 22686 22539 22392 21950 21214
1/3 (33%) 2606 0.43 0.228 22659 22219 21781 2465 1728
1/6 (17%) 2300 0.21 0.114 22643 21754 2877 1754 6140
1/12 (8%) 2147 0.11 0.057 22599 2825 930 6193 14965
GOLD1
No intervention (0%) 11612 21.12 11.869
Reference case (100%) 22004 1.29 0.721 22779 22641 22502 22086 21393
1/3 (33%) 2677 0.43 0.241 22808 22394 21979 2734 1340
1/6 (17%) 2337 0.22 0.122 22770 21943 21123 1336 5434
1/12 (8%) 2175 0.11 0.061 22864 21230 410 5328 13525
GOLD2
No intervention (0%) 31031 15.14 7.804
Reference case (100%) 23171 1.33 0.686 24624 24477 24331 23894 23165
1/3 (33%) 21062 0.45 0.230 24626 24183 23748 22443 2270
1/6 (17%) 2523 0.22 0.114 24568 23711 22833 2202 4184
1/12 (8%) 2258 0.11 0.057 24516 22772 21018 4246 13018
GOLD3
No intervention (0%) 48422 10.87 5.548
Reference case (100%) 1366 1.16 0.641 2133 2287 2443 2911 3691
1/3 (33%) 438 0.38 0.214 2044 2514 2981 4383 6720
1/6 (17%) 224 0.19 0.107 2093 3028 3963 6766 11439
1/12 (8%) 106 0.09 0.053 2013 3887 5774 11434 20868
GOLD4
No intervention (0%) 75222 10.33 4.288
Reference case (100%) 7349 1.11 0.419 17546 17778 18017 18733 19926
1/3 (33%) 2454 0.37 0.140 17547 18243 18957 21100 24671
1/6 (17%) 1219 0.18 0.069 17548 19116 20565 24913 32159
1/12 (8%) 605 0.09 0.034 17547 20735 23676 32500 47206
COPD, chronic obstructive pulmonary disease; QALY, quality adjusted life-years; ICER, incremental cost-effectiveness ratio: additional cost (positive values) or savings
(negative values) per unit of QALY gained.
All values except those corresponding to no intervention (cohorts in which all patients smoke at simulation initiation) represent incremental costs, incremental health
outcomes, or incremental cost-effectiveness, as compared to no intervention.
doi:10.1371/journal.pone.0024870.t004
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attractive: an intervention targeted to GOLD2 patients, costing
200 £ and having a success rate of only 8% (lower than the 12.3%
success rate for a COPD patient reported in a review [9,10]),
would yield an ICER of 21018 £/QALY. We examined how the
results were affected by varying the smoking cessation rate
(Table 4), a parameter associated with a substantial uncertainty.
In the general population, 9 to 12 weeks of pharmacological
therapy might cost between £81.56 and £165.66, and yield a 12-
month abstinence rate of between 3% and 23% [26,27]. A review
[28] of smoking cessation interventions in COPD patients (general
COPD population, general practitioners, hospital inpatients)
reported 12-month abstinence rates ranging from 4.5% [29] to
34.5% [30]. COPD patients are more depressed and prone to
relapse [31]. They might find it more difficult to quit than smokers
in the general population, but current and future social and
medical pressures might increase the quit rates. Smoking cessation
programmes specifically dedicated to COPD patients might cost
more than those targeted to a general population of smokers, but
our study explored a large range of costs for such programmes,
and a favourable ICER was obtained with most of the postulated
smoking cessation rates and intervention costs.
Three medico-economic studies [9,10,32] focused on the impact
of smoking on Dutch COPD patients. The first study [32]
estimated the impact of changes in demographics and tobacco
consumption on COPD morbidity, mortality and costs during a
20-year period, and indicated that 90% of disease costs were
accounted for by COPD patients who were current or ex-smokers.
The two other studies [9,10] analyzed the consequences of various
smoking cessation programmes on COPD patients during a 25-
year period. In particular, a programme involving intensive
counseling plus pharmacotherapy dominated the other interven-
tions [9]. The underlying models [10,32] considered COPD
included predictions of the impact of incident COPD during the
study period. Such a perspective has the advantage of cumulating
the whole burden (associated with current and future patients)
within a fixed horizon time. At the opposite, a disadvantage of
such a perspective is that incidence data being censored, the
estimates in patient-years cannot be converted to estimates per
patient. In contrast, our study based on current COPD data for
England, is patient-centred. The proposed simulations followed all
cohort members until death and detail the cost-effectiveness
impact of smoking cessation according to disease severity,
examining simultaneously various potential costs of smoking
cessation programmes and various potential rates of associated
quit rates. To our knowledge, the patient estimates reported in the
present study have never yet been reported. Moreover, the
material provided in the present study may also be viewed as a
proposed accessible tool for exploring in details the medico-
economic impact of smoking cessation in COPD patients,
assuming a wide range of hypotheses.
The results of this study are limited by uncertainties on some of
the parameter values. For example, the transition rates between
severity stages [17] were not specific to the English population of
COPD patients, and mortality rates by age and smoking status
among English COPD patients have not been reported.
Nevertheless, varying the transition rates and the mortality rates
(COPD-related mortality is thought to be underestimated [33,34])
did not markedly affect the ICERs (Figure 2). Another problem
concerns exacerbations, for which there is no agreed definition
[35]. Our results indicate that smoking cessation remains cost-
effective even when the proportion of exacerbation-free patients
increases or when ex-smokers experience fewer exacerbations
(Figure 2). Other uncertainties concern the costs of the disease.
Figure 2. Sensitivity analysis. In each of the A to K explored scenarios (top to bottom), the value of a key parameter was changed as compared to
the reference case scenario. For each of these scenarios, the figure indicates how simulation outputs (i.e. difference D between intervention and non
intervention in terms of QALY, Cost, ICER) change, as compared to the simulation outputs of the reference scenario (reference case for which DQALY,
DCost, DICER were 0.679 QALY, 21824 £ and 22686 £/QALY, respectively, see Table 1 for parameter values and Table 3 for more detailed simulation
outputs). For example, in scenario A, DQALY, DCost, DICER were 0.817 QALY, 21262 £ and 21544 £/QALY, therefore representing respectively a 20%
((0,81720,679)/0,679), a 231%, and a 242% change, as compared to the reference case scenario. Scenarios A to K correspond to the following
modifications of parameter values as compared to those used in the reference case: A, the proportion of exacerbation-free patients among ex-
smokers was raised by 30%; B, the increased risks of death in COPD patients (as compared to individuals of the standard population were set to the
upper limits reported by Mannino et al [21]; C, the probability of death was increased by 30%; D, the increased risks of death in COPD patients (as
compared to individuals of the standard population) were set to the lower limit reported by Mannino et al [21]; E, the proportion of exacerbation-free
patients among ex-smokers was raised by 15%; F, health utilities and costs were not discounted; G, no disease management costs for GOLD1 patients;
H, the proportion of exacerbation-free patients was raised by 15%; I, health utilities and costs were discounted at the rate of 5%; J, disease
management costs increased by 15% for each severity stage; K, the transition rate from one stage to the next was increased by 30%.
doi:10.1371/journal.pone.0024870.g002
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general population, and our model parameter values were thus
based on Swedish data. Nevertheless, our results were not very
sensitive to variations in such costs. This may be due to the initially
high proportion of patients in stage GOLD1, which is associated
with negligible costs but adding 15% to the cost of each severity
stage resulted in only moderate changes in the simulation outputs
(Figure 2). Second, neither the relative frequency of comorbidities
in COPD smokers and ex-smokers have been reported, neither
their associated specific cost. Since such costs were therefore not
taken into account in the simulations whereas the corresponding
health outcomes were (health utilities and all-cause death rates
used in the simulations include comorbidities), the cost-effective-
ness estimates issued from the simulations should be considered as
a lower limit, the value of the increase in these estimates related to
taking into account the costs of comorbidities (likely more
important in COPD smokers than in COPD ex-smokers)
remaining to be studied. The dependency of the results on the
chosen values of certain parameters is also useful for guiding
design and data collection in future studies, in order to obtain
estimates of better quality. More precise estimates of transition
rates between severity stages, mortality and exacerbation rates,
patient age distribution and background changes in smoking status
would help to guide new strategies designed to improve COPD
patient management. Most of all, even if sensitivity analysis did not
outline any critical inappropriate parameter value used in our
model, since the health conditions and medical treatment choices
improve every year, more recent parameter values than those used
in our study would improve the quality of the model outputs.
In conclusion, this study indicates that smoking cessation by
English COPD patients would be associated with gains in life
expectancy and quality of life, and with a reduction in disease-
related costs. These gains might be considered as modest for the
individual patient but are substantial from society’s standpoint.
Smoking cessation interventions focusing on GOLD1 and
GOLD2 patients are expected to be particularly beneficial, even
if devoted programmes, likely more expensive than interventions
in other populations, are considered.
Supporting Information
Table S1 Initial age distributions (% of patients) of English
COPD smoking patients according to severity.
(DOC)
Table S2 Transition probabilities from a severity stage to the
next.
(DOC)
Table S3 Probability of Death of a COPD patient according to
age, smoking status, and severity.
(DOC)
Author Contributions
Conceived and designed the experiments: CC GH. Performed the
experiments: KA. Analyzed the data: KA. Wrote the paper: KA GH.
Revised the paper: CC. Coordinated the study: GH.
References
1. Mathers CD, Loncar D (2006) Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 3: e442.
2. Mannino DM, Buist AS (2007) Global burden of COPD: risk factors,
prevalence, and future trends. Lancet 370: 765–773.
3. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, et al. (2000)
Smoking cessation and lung function in mild-to-moderate chronic obstructive
pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161:
381–390.
4. Christakis NA, Fowler JH (2008) The collective dynamics of smoking in a large
social network. N Engl J Med 358: 2249–2258.
5. Goodman PG, Haw S, Kabir Z, Clancy L (2009) Are there health benefits
associated with comprehensive smoke-free laws. Int J Public Health 54:
367–378.
6. Orleans CT, Jepson C, Resch N, Rimer BK (1994) Quitting motives and
barriers among older smokers. The 1986 Adult Use of Tobacco Survey revisited.
Cancer 74: 2055–2061.
7. Shahab L, Jarvis MJ, Britton J, West R (2006) Prevalence, diagnosis and relation
to tobacco dependence of chronic obstructive pulmonary disease in a nationally
representative population sample. Thorax 61: 1043–1047.
8. Parrott S, Godfrey C (2004) Economics of smoking cessation. BMJ 328:
947–949.
9. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP
(2010) Long-term effectiveness and cost-effectiveness of smoking cessation
interventions in patients with COPD. Thorax 65: 711–718.
10. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML,
Buist AS, et al. (2005) A dynamic population model of disease progression in
COPD. Eur Respir J 26: 223–233.
11. National Institute for Health and Clinical Excellence. Guide to the methods of
technology appraisal. Available: http://www.nice.org.uk/aboutnice/howwe
work/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftech
nologyappraisal.jsp. Accessed july 2010.
12. Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for
reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and
Medicine. JAMA 276: 1339–1341.
13. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a
practical guide. Med Decis Making 13: 322–338.
14. Global Initiative for Chronic Obstructive Lung Disease (2009) Global strategy
for the Diagnosis. Management. and Prevention of Chronic Obstructive
Pulmonary Disease: updated. Available: http://www.goldcopd.com/download.
asp?intId=554. Accessed July 2010.
15. Lindberg A, Bjerg A, Ronmark E, Larsson LG, Lundback B (2006) Prevalence
and underdiagnosis of COPD by disease severity and the attributable fraction of
smoking Report from the Obstructive Lung Disease in Northern Sweden
Studies. Respir Med 100: 264–272.
16. Office For National Statistics (2008) Population Estimates for England Mid Year
2008. Available: http://www.statistics.gov.uk/downloads/theme_population/
mid-2008-improved-migration-revised-13-05-10.zip. Accessed August 2010.
17. Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, et al. (2009)
Present and future costs of COPD in Iceland and Norway: results from the
BOLD study. Eur Respir J 34: 850–857.
18. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E,
Navarro M, et al. (2005) Severe acute exacerbations and mortality in patients
with chronic obstructive pulmonary disease. Thorax 60: 925–931.
19. Eurostat (2007) European statistic database. Available: http://epp.eurostat.ec.
europa.eu/portal/page/portal/health/public_health/database. Accessed July
2010.
20. Mannino DM, Doherty DE, Sonia Buist A (2006) Global Initiative on
Obstructive Lung Disease (GOLD) classification of lung disease and mortality:
findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir
Med 100: 115–122.
21. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG (2005)
Mortality in GOLD stages of COPD and its dependence on symptoms of
chronic bronchitis. Respir Res 6: 98.
22. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, et al. (2002) Costs of
COPD in Sweden according to disease severity. Chest 122: 1994–2002.
23. The Economist (2010) The Economist’s Big Mac index. Big Mac index.
Available: http://www.economist.com/markets/bigmac/. Accessed July 2010.
24. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, et al. (2004) A
computer simulation model of the natural history and economic impact of
chronic obstructive pulmonary disease. Value Health 7: 153–167.
25. Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking:
50 years’ observations on male British doctors. BMJ 328: 1519.
26. Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine
replacement therapy for smoking cessation. Cochrane Database Syst Rev. pp
CD000146.
27. Taylor DC, Chu P, Rosen VM, Baker CL, Thompson D (2009) Budgetary
impact of varenicline in smoking cessation in the United Kingdom. Value
Health 12: 28–33.
28. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, et al. (2009) Smoking
cessation interventions in COPD: a network meta-analysis of randomised trials.
Eur Respir J 34: 634–640.
29. Tonnesen P, Mikkelsen K, Bremann L (2006) Nurse-conducted smoking
cessation in patients with COPD using nicotine sublingual tablets and behavioral
support. Chest 130: 334–342.
Smoking Cessation in COPD Smokers
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e2487030. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, et al. (1994)
Effects of smoking intervention and the use of an inhaled anticholinergic
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA
272: 1497–1505.
31. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP (2005)
Efficacy of bupropion and nortriptyline for smoking cessation among people at
risk for or with chronic obstructive pulmonary disease. Arch Intern Med 165:
2286–2292.
32. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van
Molken MP (2001) The impact of aging and smoking on the future burden of
chronic obstructive pulmonary disease: a model analysis in the Netherlands.
Am J Respir Crit Care Med 164: 590–596.
33. Jensen HH, Godtfredsen NS, Lange P, Vestbo J (2006) Potential misclassifica-
tion of causes of death from COPD. Eur Respir J 28: 781–785.
34. Mannino DM, Kiriz VA (2006) Changing the burden of COPD mortality.
Int J Chron Obstruct Pulmon Dis 1: 219–233.
35. Atsou K, Chouaid C, Hejblum G (2011) Variability of the chronic obstructive
pulmonary disease key epidemiological data in Europe: systematic review. BMC
Med 9: 7.
Smoking Cessation in COPD Smokers
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24870